



Simin Dadashzadeh (Pharm.D., Ph.D.)

Professor of Pharmaceutics

Contact information

Department of Pharmaceutics and Nanotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Vali-e-asr Ave., Niayesh junction, PO Box: 14155-6153, Tehran, Iran.

Phone: +98 21-88200070,

Fax: +98 21-88209620

Email: Sdadashzadeh@sbm.ac.ir

Specialization: Biopharmaceutics & Pharmacokinetics

Academic positions

1. Professor, Shahid Beheshti University of Medical Sciences, Tehran, Iran, 2010-Present
2. Associate Professor of Pharmaceutics, Shahid Beheshti University of Medical Sciences, Tehran, Iran, 2003-Oct 2010.
3. Assistant Professor of Pharmaceutics, Shahid Beheshti University of Medical Sciences, Tehran, Iran, 1996 – 2002.
4. Instructor of Pharmaceutics, Shahid Beheshti University of Medical Sciences, Tehran, Iran, 1991-1995.

Education

Pharm. D: Tabriz University, Iran, 1985.

Ph.D.: School of Pharmacy, Tehran University of Medical Sciences, 1995.

Postdoc: University of Ottawa, Ottawa, Canada, 1996.

Research Interests

- Nanotechnology
- Design and development of drug delivery systems (liposomes, niosomes, cerasomes, micelles and polymeric nanoparticles) with emphasis on the treatment of cancer and cardiovascular diseases.

- Tuning the physicochemical characteristics of particle-based Carriers for loco-regional drug delivery and evaluation of their in vivo disposition.
- Biopharmaceutics and Pharmacokinetics
- Enhancement of oral drug absorption using diverse formulation approaches.
- Pharmacokinetics (absorption, distribution and elimination) of drugs and their metabolites.

publications

1. Preparation of multivesicular liposomes for the loco-regional delivery of Vancomycin hydrochloride using active loading method: drug release and antimicrobial properties.

Vatankhah M, Dadashzadeh S, Mahboubi A, Haeri A, Jandaghi Alae K, Mostafavi Naeini SB, Abbasian Z.

J Liposome Res. 2023 Jun 7:1-11. doi: 10.1080/08982104.2023.2220805.

2. Berberine-phospholipid nanoaggregate-embedded thiolated chitosan hydrogel for aphthous stomatitis treatment.

Hashtrodyar Y, Rabbani S, Dadashzadeh S, Haeri A.

Nanomedicine (Lond). 2023 Aug;18(19):1227-1246. doi: 10.2217/nmm-2023-0009.

3. Piperine-loaded electrospun nanofibers, an implantable anticancer controlled delivery system for postsurgical breast cancer treatment

Babadi D, Dadashzadeh S, Shahsavari Z, Shahhosseini S, Ten Hagen TLM, Haeri A.

Int J Pharm. 2022 Aug 25;624:121990. doi: 10.1016/j.ijpharm.2022.121990.

4. Piperine liposome-embedded in hyaluronan hydrogel as an effective platform for prevention of postoperative peritoneal adhesion.

Karimi H, Rabbani S, Babadi D, Dadashzadeh S, Haeri A.

J Microencapsul. 2023 Jun;40(4):279-301. doi: 10.1080/02652048.2023.2194415.

5. Doxorubicin-Loaded Multivesicular Liposomes (DepoFoam) as a Sustained Release Carrier Intended for Locoregional Delivery in Cancer Treatment: Development, Characterization, and Cytotoxicity Evaluation.

Mahjoub MA, Dadashzadeh S, Haeri A, Shahhosseini S, Abbasian Z, Nowroozi F.

Iran J Pharm Res. 2023 Feb 26;21(1):e134190. doi: 10.5812/ijpr-134190

6. Sirolimus-exuding core-shell nanofibers as an implantable carrier for breast cancer therapy: preparation, characterization, in vitro cell studies, and in vivo anti-tumor activity.

Talimi R, Shahsavari Z, Dadashzadeh S, Ten Hagen TLM, Haeri A.

Drug Dev Ind Pharm. 2022 Dec;48(12):694-707. doi: 10.1080/03639045.2022.2161559.

7. The Impact of Process and Formulation Parameters on the Fabrication of Efavirenz Nanosuspension to Improve Drug Solubility and Dissolution.

Rashed M, Dadashzadeh S, Bolourchian N.

Iran J Pharm Res. 2022 Sep 23;21(1):e129409. doi: 10.5812/ijpr-129409.

8. Particle Size Tailoring of Quercetin Nanosuspensions by Wet Media Milling Technique: A Study on Processing and Formulation Parameters.

Cheshmehnoor P, Bolourchian N, Abdollahizad E, Derakhshi A, Dadashzadeh S, Haeri A.

Iran J Pharm Res. 2023 Feb 1;21(1):e130626. doi: 10.5812/ijpr-130626.

9. Pharmacokinetics, tissue distribution and peritoneal retention of Ag₂S quantum dots following intraperitoneal administration to mice.

Mahlooji I, Javidi J, Dadashzadeh S.

J Pharm Pharmacol. 2021 Dec 7;73(12):1599-1608. doi: 10.1093/jpp/rgab118.

10. Multivesicular liposomal depot system for sustained delivery of risperidone: development, characterization, and toxicity assessment.

Alavi S, Mahjoob MA, Haeri A, Shirazi FH, Abbasian Z, Dadashzadeh S.

Drug Dev Ind Pharm. 2021 Oct 15;1-12. doi: 10.1080/03639045.2021.1989454.

11. Multivesicular liposomes as a potential drug delivery platform for cancer therapy: A systematic review

Naeini, S.B.M., Dadashzadeh, S., Haeri, A., ...Javidi, J., Vatankhah, M.

Journal of Drug Delivery Science and Technology, 2021, 66, 102842

12. Ameliorative effect of a nano chromium metal-organic framework on experimental diabetic chronic kidney disease.

Fakharzadeh S, Kalanaky S, Argani H, Dadashzadeh S, Torbati PM, Nazaran MH, Basiri A.

Drug Dev Res. 2021 May;82(3):393-403. doi: 10.1002/ddr.21759.

13. Nanoformulation strategies for improving intestinal permeability of drugs: A more precise look at permeability assessment methods and pharmacokinetic properties changes.

Babadi D, Dadashzadeh S, Osouli M, Daryabari MS, Haeri A.

J Control Release. 2020 May 10;321:669-709. doi: 10.1016/j.jconrel.2020.02.041. Review.

14. An investigation of affecting factors on MOF characteristics for biomedical applications: A systematic review.

Ahmadi M, Ayyoubzadeh SM, Ghorbani-Bidkorbbeh F, Shahhosseini S, Dadashzadeh S, Asadian E, Mosayebnia M, Siavashy S.

Heliyon. 2021 Apr 27;7(4):e06914. doi: 10.1016/j.heliyon.2021.e06914 .

15. An enzyme-mediated controlled release system for curcumin based on cyclodextrin/cyclodextrin degrading enzyme.

Roozbehi S, Dadashzadeh S, Sajedi RH.
Enzyme Microb Technol. 2021 Mar;144:109727. doi: 10.1016/j.enzmictec.2020.109727.

16. Tuning the Physicochemical Characteristics of Particle-Based Carriers for Intraperitoneal Local Chemotherapy.

Alavi S, Haeri A, Mahlooji I, Dadashzadeh S.
Pharm Res. 2020 Jun 3;37(6):119. doi: 10.1007/s11095-020-02818-8.

17. - The Impact of Surfactant Composition and Surface Charge of Niosomes on the Oral Absorption of Repaglinide as a BCS II Model Drug.

Yaghoobian M, Haeri A, Bolourchian N, Shahhosseni S, Dadashzadeh S.
Int J Nanomedicine. 2020 Nov 11;15:8767-8781. doi: 10.2147/IJN.S261932.

18. Targeted anticancer prodrug therapy using dextran mediated enzyme-antibody conjugate and β -cyclodextrin-curcumin inclusion complex.

Roozbehi S, Dadashzadeh S, Mirshahi M, Sadeghizadeh M, Sajedi RH.
Int J Biol Macromol. 2020 Oct 1;160:1029-1041. doi: 10.1016/j.ijbiomac.2020.05.225.

19. DIBc nano metal-organic framework improves biochemical and pathological parameters of experimental chronic kidney disease.

Fakharzadeh S, Argani H, Torbati PM, Dadashzadeh S, Kalanaky S, Nazaran MH, Basiri A.
J Trace Elem Med Biol. 2020 May 11;61:126547. doi: 10.1016/j.jtemb.2020.126547.

20. BCc1 Nanomedicine Therapeutic Effects in Streptozotocin and High-Fat Diet Induced Diabetic Kidney Disease.

Fakharzadeh S, Argani H, Dadashzadeh S, Kalanaky S, Mohammadi Torbati P, Nazaran MH, Basiri A.
Diabetes Metab Syndr Obes. 2020 Apr 17;13:1179-1188. doi: 10.2147/DMSO.S240757.

21. A microdosimetry model of kidney by GATE Monte Carlo simulation using a nonuniform activity distribution in digital phantom of nephron.

Jabari M, Rajabi H, Dadashzadeh S.
Nucl Med Commun. 2020 Feb;41(2):110-119. doi: 10.1097/MNM.0000000000001112.

22. Pharmacokinetics, Tissue Distribution and Excretion of Ag₂S Quantum Dots in Mice and Rats: the Effects of Injection Dose, Particle Size and Surface Charge.

Javidi J, Haeri A, Nowroozi F, Dadashzadeh S.
Pharm Res. 2019 Feb 4; 36(3):46.

23. Green formulation of curcumin loaded lipid-based nanoparticles as a novel carrier for inhibition of post-angioplasty restenosis.

Akhlaghi S, Rabbani S, Alavi S, Alinaghi A, Radfar F, Dadashzadeh S, Haeri A.
Mater Sci Eng C Mater Biol Appl. 2019 Dec; 105:110037. doi: 10.1016/j.msec.2019.110037.

24. An Investigation into the Role of P-Glycoprotein in the Intestinal Absorption of Repaglinide: Assessed by Everted Gut Sac and Caco-2 Cell Line.

Yaghoobian M, Haeri A, Bolourchian N, Shahhosseini S, Dadashzadeh S.
Iran J Pharm Res. 2019 Winter;18(1):102-110.

25. Tadalafil nanocomposites as a dry powder formulation for inhalation, a new strategy for pulmonary arterial hypertension treatment.

Teymouri Rad R, Dadashzadeh S, Vatanara A, Alavi S, Ghasemian E, Mortazavi SA.
Eur J Pharm Sci. 2019 May 15;133: 275-286.

26. Evaluation of Cyclosporine Pharmacokinetic, Monitoring, and Dosing Parameters for GVHD Prophylaxis in Hematopoietic Stem Cell Transplant (HSCT) Recipients.

Tafazoli A, Dadashzadeh S, Mehdizadeh M, Parkhideh S, Tavakoli-Ardakani M.
Iran J Pharm Res. 2019 Fall;18(Suppl1):302-314. doi: 10.22037/ijpr.2020.112111.13539.

27. Radiolabeling of Preformed Niosomes with [99mTc]: In Vitro Stability, Biodistribution, and In Vivo Performance.

Almasi A, Shahhosseini S, Haeri A, Doha FJ, Geramifar P, Dadashzadeh S.
AAPS PharmSciTech. 2018 Nov;19(8):3859-3870.

28. Labrasol-Enriched Nanoliposomal Formulation: Novel Approach to Improve Oral Absorption of Water-Insoluble Drug, Carvedilol.

Ghassemi S, Haeri A, Shahhosseini S, Dadashzadeh S.
AAPS PharmSciTech. 2018 Oct;19(7):2961-2970.

29. Theranostic niosomes for direct intratumoral injection: marked enhancement in tumor retention and anticancer efficacy.

Nowroozi F, Dadashzadeh S, Soleimanjahi H, Haeri A, Shahhosseini S, Javidi J, Karimi H.
Nanomedicine (Lond). 2018 Sep;13(17):2201-2219.

30. Green Formulation of Triglyceride/Phospholipid-Based Nanocarriers as a Novel Vehicle for Oral Coenzyme Q10 Delivery.

Alavi S, Akhlaghi S, Dadashzadeh S, Haeri A.
J Food Sci. 2019 Sep;84(9):2572-2583.

31. Doxorubicin-loaded liposomes: enhancing the oral bioavailability by modulation of physicochemical characteristics.

Daeihamed M, Haeri A, Ostad SN, Akhlaghi MF, Dadashzadeh S*.
Nanomedicine (Lond). 2017 May; 12(10):1187-1202. doi: 10.2217/nmm-2017-0007

32. Utilization of chitosan-caged liposomes to push the boundaries of therapeutic delivery.

Alavi S, Haeri A, Dadashzadeh S*.

Carbohydrate Polymer. 2017 Feb 10; 157:991-1012. doi: 10.1016/j.carbpol.2016.10.063.

33. Effective attenuation of vascular restenosis following local delivery of chitosan decorated sirolimus liposomes.

Haeri A, Sadeghian S, Rabbani S, Anvari MS, Ghassemi S, Radfar F, Dadashzadeh S*.

Carbohydrate Polymer. 2017 Feb 10; 157:1461-1469. doi: 10.1016/j.carbpol.2016.11.021.

34. Physicochemical characteristics of liposomes are decisive for their antirestenosis efficacy following local delivery.

Haeri A, Sadeghian S, Rabbani S, Shirani S, Anvari MS, Dadashzadeh S.

Nanomedicine (Lond). 2017 Jan;12 (2):131-145..

35. Physicochemical, Stress Degradation Evaluation and Pharmacokinetic Study of AZGH101; a New Synthesized COX2 Inhibitor after I.V. and Oral Administration in Male and Female Rats.

Bahmanof H, Dadashzadeh S, Zarghi A, Shafaati A, Foroutan SM.

Iran J Pharm Res. 2018 Winter;17 (1):115-123.

36. Enhanced Dissolution Rate of Tadalafil Nanoparticles Prepared by Sonoprecipitation Technique: Optimization and Physicochemical Investigation.

Teymouri Rad R, Mortazavi SA, Vatanara A, Dadashzadeh S.

Iran J Pharm Res. 2017 Fall;16(4):1335-1348.

37. State of the Art of Stimuli-Responsive Liposomes for Cancer Therapy.

Heidarli E, Dadashzadeh S, Haeri A.

Iran J Pharm Res. 2017 Fall;16(4):1273-1304.

38. Controlled SLN Delivery by Thermoresponsive In-situ Forming Erodible Gels; A Whole-body and Organ Imaging Study.

Dorraj G, Dadashzadeh S, Erfan M, Moghimi HR.

Curr Drug Deliv. 2018;15(4):510-519.

39. Administration of Vancomycin at High Doses in Patients with Post Neurosurgical Meningitis: A Comprehensive Comparison between Continuous Infusion and Intermittent Infusion.

Taheri M, Dadashzadeh S, Shokouhi S, Ebrahimzadeh K, Sadeghi M, Sahraei Z.

Iran J Pharm Res. 2018;17(Suppl2):195-205.

40. Preparation, In-Vitro Characterization and Pharmacokinetic Evaluation of Brij Decorated Doxorubicin Liposomes as a Potential Nanocarrier for Cancer Therapy.

Fazel M, Daeihamed M, Osouli M, Almasi A, Haeri A, Dadashzadeh S.

Iran J Pharm Res. 2018;17(Suppl2):33-43.

41. Effect of Surfactant Type, Cholesterol Content and Various Downsizing Methods on the Particle Size of Niosomes.

Nowroozi F, Almasi A, Javidi J, Haeri A, Dadashzadeh S.

Iran J Pharm Res. 2018;17 (Suppl2):1-11.

42. Nanomedicine approaches for sirolimus delivery: a review of pharmaceutical properties and preclinical studies.

Haeri A(1)(2), Osouli M(1), Bayat F(1), Alavi S(1), Dadashzadeh S(1).

Artif Cells Nanomed Biotechnol. 2018;46(sup1):1-14.

43. Physicochemical, Stress Degradation Evaluation and Pharmacokinetic Study of AZGH102, a New Synthesized COX2 Inhibitors after I.V. and Oral Administration in Male and Female Rats.

Bahmanof H, Dadashzadeh S, Zarghi A, Shafaati A, Foroutan SM

Iran J Pharm Res. 2017 Spring;16(2):442-450.

44. Dorzolamide Loaded Niosomal Vesicles: Comparison of Passive and Remote Loading Methods.

Hashemi Dehaghi M, Haeri A, Keshvari H, Abbasian Z, Dadashzadeh S.

Iran J Pharm Res. 2017 Spring;16(2):413-422.

45. Chitosan gel-embedded moxifloxacin niosomes: An efficient antimicrobial hybrid system for burn infection.

Sohrabi S, Haeri A, Mahboubi A, Mortazavi A, Dadashzadeh S*.

International Journal of Biological Macromolecules, 2016, 85:625-33. doi: 10.1016/j.ijbiomac.2016.01.013.

46. Potential of Liposomes for Enhancement of Oral Drug Absorption.

Daeihamed M, Dadashzadeh S*, Haeri A, Akhlaghi MF.

Current Drug Delivery, 2016, Jan 15. [Epub ahead of print]

47. A Novel Combined Approach of Short-Chain Sphingolipids and Thermosensitive Liposomes for Improved Drug Delivery to Tumor Cells.

Haeri A, Pedrosa LR, Ten Hagen TL, Dadashzadeh S, Koning GA.

Journal of Biomedical Nanotechnology, 2016, 4:630-44.

48. EGFR targeted thermosensitive liposomes: A novel multifunctional platform for simultaneous tumor targeted and stimulus responsive drug delivery.

Haeri A, Zalba S, Ten Hagen TL, Dadashzadeh S, Koning GA.

Colloids Surf B Biointerfaces. 2016, 146:657-69. doi: 10.1016/j.colsurfb.2016.06.012.

49. A 16 Month Survey of Cyclosporine Utilization Evaluation in Allogeneic Hematopoietic Stem Cell Transplant Recipients.

Tavakoli Ardakani M, Tafazoli A, Mehdizadeh M, Hajifathali A, Dadashzadeh S.
Iranian Journal of Pharmaceutical Research, 2016 Winter;15(1):331-9.

50. Niosomal carriers enhance oral bioavailability of carvedilol: effects of bile salt-enriched vesicles and carrier surface charge.

Arzani G, Haeri A, Daeihamed M, Bakhtiari-Kaboutaraki H, Dadashzadeh S*.
International Journal of Nanomedicine. 2015, 10:4797-813. doi: 10.2147/IJN.S84703.

51. A Simple and Sensitive HPLC Method for Fluorescence Quantitation of Doxorubicin in Micro-volume Plasma: Applications to Pharmacokinetic Studies in Rats

Daeihamed M, Haeri A, Dadashzadeh S*.
Iranian Journal of Pharmaceutical Research, 2015,14(Suppl):33-42.

52. Effects of cyclosporine A on the hepatobiliary disposition and hepatic uptake of etoposide in an isolated perfused rat liver model.

Khezrian M, Sheikholeslami B, Dadashzadeh S, Lavasani H, Rouini M.
Cancer Chemotherapy Pharmacology, 2015, 75(5):961-8. doi: 10.1007/s00280-015-2719-6.

53. Marked effects of combined TPGS and PVA emulsifiers in the fabrication of etoposide-loaded PLGA-PEG nanoparticles: in vitro and in vivo evaluation.

Saadati R, Dadashzadeh S*.
International Journal of Pharmaceutics, 2014, 464(1-2):135-44. doi: 10.1016/j.ijpharm.2014.01.014.

54. Preparation and characterization of stable nanoliposomal formulation of fluoxetine as a potential adjuvant therapy for drug-resistant tumors.

Haeri A, Alinaghian B, Daeihamed M, Dadashzadeh S*.
Iranian Journal of Pharmaceutical Research. 2014, 13(Suppl):3-14.

55. A 16 Month Survey of Cyclosporine Utilization Evaluation in Allogeneic Hematopoietic Stem Cell Transplant Recipients.

Tavakoli Ardakani M, Tafazoli A, Mehdizadeh M, Hajifathali A, Dadashzadeh S.
Iranian Journal of Pharmaceutical Research, 2016, 15(1):331-9.

56. Sirolimus-loaded stealth colloidal systems attenuate neointimal hyperplasia after balloon injury: A comparison of phospholipid micelles and liposomes.

Haeri A, Sadeghian S, Rabbani S, Anvari MS, Lavasanifar A, Amini M, Dadashzadeh S*.
International Journal of Pharmaceutics, 2013, 455(1-2):320-30. doi: 10.1016/j.ijpharm.2013.07.003.

57. Accelerated blood clearance of PEGylated PLGA nanoparticles following repeated injections: effects of polymer dose, PEG coating, and encapsulated anticancer drug.

Saadati R, Dadashzadeh S*, Abbasian Z, Soleimanjahi H.

Pharmaceutical Research, 2013, 30:985-995.

58. Co-delivery of doxorubicin and PSC 833 (Valspodar) by stealth nanoliposomes for efficient overcoming of multidrug resistance.

Bajelan E, Haeri A, Vali AM, Ostad SN, Dadashzadeh S*,

Journal of Pharmacy and Pharmaceutical Sciences, 2012, 15(4): 568 – 582.

59. Metabolite parameters as an appropriate alternative approach for assessment of bioequivalence of two verapamil formulations.

Haeri A, Javadian B, Saadati R, Dadashzadeh S*

Iranian Journal of Pharmaceutical Research, 2014, 13(2):383-9.

60. PEGylated estradiol benzoate liposomes as a potential local vascular delivery system for treatment of restenosis.

Haeri A, Sadeghian S, Rabbani S, Anvari MS, Erfan M, Dadashzadeh* S.

Journal of Microencapsulation, 2012; 29(1):83-94.

61. Use of remote film loading methodology to entrap sirolimus into liposomes: Preparation, characterization and in vivo efficacy for treatment of restenosis.

Haeri A, Sadeghian S, Rabbani S, Anvari MS, Boroumand MA, Dadashzadeh S*,

International Journal of Pharmaceutics, 2011; 414:16-27.

62. Enhanced Permeability of Etoposide across Everted Sacs of Rat Small Intestine by Vitamin E-TPGS.

Parsa AH, Saadati R, Abbasian Z, Azad Aramakib S, Dadashzadeh S*

Iranian Journal of Pharmaceutical Research, 2013, 12: 35-44.

63. The Effect of PEG molecular weights on dissolution behavior of simvastatin in solid dispersions.

Bolourchian N, Mahboobian MM, Dadashzadeh S*.

Iranian Journal of Pharmaceutical Research, 2013, 12: 9-18

64. Simple and efficient HPLC-UV quantitation of etoposide and its cis-isomer in rat micro-volume plasma and tissue samples: Application to pharmacokinetic and biodistribution studies.

Saadati R, Dadashzadeh* S,

Journal of Liquid Chromatography & Related Technologies, 2011, 34(18): 2130-2148.

65. Peritoneal retention of liposomes: Effects of lipid composition, PEG coating and liposome charge.

Dadashzadeh* S, Mirahmadi N, Babaei MH, Vali AM,
Journal of Controlled Release, 2010; 148: 177-186.

66. Preclinical Pharmacokinetics of KBF611 a new antituberculosis agent in mice and rabbits and comparison with thiacetazone.

Mostafavi Shahab F, Kobarfard F, Shafaghi B, Dadashzadeh* S.
Xenobiotica. 2010; 40(30): 225-34.

67. Effect of liposome size on peritoneal retention and organ distribution after intraperitoneal injection in mice.

Mirahmadi N, Babaei MH, Vali A.M, Dadashzadeh* S.
International Journal of Pharmaceutics, 2010, 383:7-13.

68. Preparation and in vitro characterization of 9 nitrocamptothecin loaded long circulating nanoparticles for delivery in cancer patients.

Derakhshandeh K, Soheli M, Dadashzadeh S, Saghiri R.
International Journal of Nanomedicine. 2010, 5:463-471.

69. Further Stimulation of Cellular Immune Responses through Association of HPV-16 E6, E7 and L1 Genes in order to produce more Effective Therapeutic DNA Vaccines in Cervical Cancer Model.

Fazeli M, Soleimanjahi H, Dadashzadeh S.
Iran J Cancer Prev. 2015, 8(1):18-23.

70. LC determination of a novel COX-2 inhibitor in mouse plasma: application to preclinical pharmacokinetic studies.

Haeri A, Shahab F.M., Arfaee S, Zarghi A, Dadashzadeh S*.
Asian Journal of Chemistry 2011, 23:3329-3333.

71. Simultaneous Determination of a New Antituberculosis Agent KBF-611 and its Deacetylated Metabolite in Mouse and Rabbit Plasma by HPLC: Application to Preclinical Pharmacokinetics.

Mostafavi Shahab F, Kobarfard F, Dadashzadeh* S.
Arch Pharm Res. 2009 32(10):1453-60.

72. 9-Nitrocamptothecin polymeric nanoparticles: cytotoxicity and pharmacokinetic studies of lactone and total forms of drug in rats.

Dadashzadeh* S, Derakhshandeh K, Shirazi FH.
Anticancer Drugs, 2008 Sep; 19(8):805-811.

73. ^{99m}Tc-HMPAO-labeled liposomes: an investigation into the effects of some formulation factors on labeling efficiency and in vitro stability.

Mirahmadi N, Babaei MH, Vali AM, Daha FJ, Kobarfard F, Dadashzadeh* S.

Nucl Med Biol. 2008; 35(3):387-92.

74. The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats.

Dadashzadeh* S, Vali AM, Rezaie M.

International Journal of Pharmaceutics. 2008; 353(1-2):251-9.

75. Preparation, optimization and characterization of topotecan loaded PEGylated liposomes using factorial design,

Vali A M, Shafaghi B, Toliyat T, Dadashzadeh* S.

Drug Development and Industrial Pharmacy 2008; 34(1):10-23.

76. pH-independent release of propranolol hydrochloride from HPMC-based matrices using organic acids.

Blourtchian N, Dadashzadeh S.

DARU 2008; 16(3) 136-142.

77. Serum and Saliva Theophylline Levels in Adult Outpatients with Asthma and Chronic Obstructive Pulmonary Disease (COPD): A Cross-Sectional Study.

Salamzadeh J, Dadashzadeh S, Habibi M, Estifaie S.

Iranian Journal of Pharmaceutical Research, 2008; 7 (1): 83-87.

78. Encapsulation of 9-nitrocamptothecin, a novel anticancer drug, in biodegradable nanoparticles: factorial design, characterization and release kinetics.

Derakhshandeh K, Erfan M, Dadashzadeh* S.

European Journal of Pharmaceutics and Biopharmaceutics, 2007; 66:34-41.

79. The effect of gender on the pharmacokinetics of verapamil and norverapamil in human.

Dadashzadeh* S, Javadian B, Sadeghian S.

Biopharmaceutics and Drug Disposition. 2006; 27 (7):329-334.

80. Comparative evaluation of carbamazepine release from single and bi-polymeric based matrices.

Bolourtchian N, Soltan Mohammadi A, Dadashzadeh S,

Journal of Pharmaceutical and Allied sciences, 2006, 3(2), 314-321.

81. Liquid chromatographic quantitation of the lactone and the total of lactone and carboxylate forms of 9-nitrocamptothecin in human plasma

Derakhshandeh K, Dadashzadeh* S.

Journal of Chromatography. B, 2005; 818: 199-204.

82. Simple and sensitive HPLC method for the simultaneous quantitation of the lactone and carboxylate forms of topotecan in human plasma.

Vali A M, Shafaghi B, Dadashzadeh S.
Journal of Chromatography. B, 2005; 818: 205-212.

83. The effect of various surfactants on release behavior of procainamide HCl from ethylcellulose based matrices.

Bolourtchian N, Sattari Javid F, Dadashzadeh S,
Iranian. Journal of Pharmaceutical. Research. 2005; 1: 13-19.

84. Radiation dose rate and urinary activity in patients with differentiated thyroid carcinoma treated with radioiodine-131; a survey in Iranian population.

Shahhoseini S, Beiki D, Dadashzadeh S, Eftekhari M, Tayebi H,
Hell J Nucl Med 2004;7(3): 192- 194.

85. Determination of radiation dose rates and urinary activity of patients received Sodium Iodide-131 for treatment of differentiated thyroid carcinoma.

Beiki D, Shahhoseini S, Dadashzadeh S, Eftekhari M, Tayebi H, Moosazadeh G.
The Iranian Journal of Nuclear Medicine, 2004, 21: 1-13

86. Time dependent pharmacokinetics of albendazole in human.

Mirfazaelian A, Rouini MR, Dadashzadeh S.,
Biopharmaceutics and Drug Disposition. 2003; 24(5): 199-204.

87. Determination of cyproterone acetate in plasma samples by high-performance liquid chromatography.

Zarghi A, Dadashzadeh S, Asgari A.
Boll Chim Farm. 2003; 142(5):220-223.

88. Pharmacokinetics and comparative bioavailability of two diltiazem tablet formulations in healthy volunteers.

Dadashzadeh S, Zarghi A, Ebrahimian J.
DARU. 2003; 11:14-18.

89. Radiation dose to the nuclear medicine nurses.

Sattari A, Dadashzadeh S., Nasiroghli G, Firoozabadi H,
Iranian Journal of Radiation Research 2004, 2(2):59-62.

90. Dose dependent pharmacokinetics of albendazole in human.

Mirfazaelian A, Rouini MR, Dadashzadeh S.
Biopharmaceutics and Drug Disposition. 2002; 23(9):379-383.

91. A high performance liquid chromatography method for simultaneous determination of albendazole metabolites in human serum.

Mirfazaelian A, Dadashzadeh S., Rouini MR.

J Pharm Biomed Anal. 2002; 30(4): 1249-1254.

92. Effect of gender in the disposition of albendazole metabolites in humans

Mirfazaelian A, Dadashzadeh S., Rouini MR.

European Journal of Clinical Pharmacology 2002; 58(6): 403-408.

93. Is albendazole sulphonation dose dependent in human ?

Rouini, M.R., Mirfazaelian, A., Dadashzadeh, S., Tabatabaiefar, M

Daru, Vol.10, No.4, Year. 2002, Page:148-152 ,

94. LC Determination of piroxicam in human plasma.

Dadashzadeh S, Vali AM, Rezagholi N.,

Journal of Pharmaceutical and Biomedical Analysis. 2002; 28(6): 1201-1204.

95. Which of the two main metabolites of albendazole is appropriate for bioequivalence studies ?

Mirfazaelian A., Dadashzadeh S., Rouini, M.R

Journal of Pharmacy and Pharmacology, Vol.52, Year. 2000, Page:84

96. Urinary excretion and external radiation dose from patients administered Tallium- 201 and Technetium-99m methoxy isobutyl isonitril.

Sattari A, Dadashzadeh S, Nasirogli G.

Radiation Protection Dosimetry. 2001; 95 (1) : 59-61

97. Dose dependent pharmacokinetics of theophylline: Michaelis- Menten parameters for its major metabolic pathways

Dadashzadeh S, Tajerzadeh H.

European Journal of Drug Metabolism and Pharmacokinetics. 2001;26 (1/2): 77-83.

98. Determination of amitriptyline in plasma samples by high-performance liquid chromatography.

Zarghi A., Dadashzadeh S, Kiayi Z.

Boll Chim Farm. 2001; 140(6) : 458-461.

99. HPLC quantitation of diltiazem in plasma from man.

Zarghi A., Dadashzadeh S, Ebrahimian A J.

Pharmacy and Pharmacology Communications. 2000; 6: 341-343.

100. An Isocratic HPLC system for simultaneous determination of theophylline and its major metabolites.

Tajerzadeh H., Dadashzadeh S.

Journal of Pharmaceutical and Biomedical Analysis. 1995; 13: 1507-1517.

Memberships

- Iranian Association of Pharmaceutical Scientists
- Iranian Society of Biopharmaceutics and Pharmacokinetics

MEMBERSHIP IN COMMITTEES

- Board of Nanotechnology, Postgraduate Students, Ministry of Health and Medical Education, IRAN.
- Nanotechnology Standard Committee, Ministry of Health and Medical Education, IRAN.
- Supreme Council of Tissue Engineering and Nanotechnology Research Center, Shahid Beheshti University of Medical Sciences.
- Supreme Council of Pharmaceutical sciences Research Center, Shahid Beheshti University of Medical Sciences.
- Faculty Promotion Committee, Shahid Beheshti University of Medical Sciences.
- Research Committee, School of Pharmacy, Shahid Beheshti University of Medical Sciences.
- Faculty Educational Development Center, Shahid Beheshti University of Medical Sciences
-